Skip to content
Home/Companies/Biotech/Atopix Therapeutics

Atopix Therapeutics

Biotech·United Kingdom·Exited 2016·Held 3yr
Entry
2013
Hold
3yr
Exit
2016

Who owns Atopix Therapeutics?

Atopix Therapeutics was owned by Wellington Partners through Wellington Partners Life Sciences (1998 vintage) from 2013 to 2016, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-10

Wellington Partners
Investor
Wellington Partners
Wellington Partners Life Sciences · 1998 · VC

Key facts

HQUnited Kingdom
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2016

More from Wellington Partners Life Sciences

Other portfolio companies in the same fund.

Beren Therapeutics
Active
BiotechUnited States· 2026
Nuclidium
Active
BiotechSwitzerland· 2026
CorFlow Therapeutics
CorFlow Therapeutics
Active
MedTechSwitzerland· 2024
SciRhom
Active
BiotechGermany· 2024
Nyra Health
Active
HealthTechAustria· 2023
Seamless Therapeutics
Seamless Therapeutics
Active
BiotechGermany· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Atopix Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Atopix Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue